HepaRG

Last updated
Fully differentiated HepaRG cells organized in well-delineated trabeculae with many bright canaliculi-like structures. HEPARGF.jpg
Fully differentiated HepaRG cells organized in well-delineated trabeculae with many bright canaliculi-like structures.

HepaRG cell line is a human hepatic in vitro line used in liver biology research and for assessing liver pathology, hepatotoxicity, and drug-induced injury. The HepaRG model is considered a surrogate for Primary Human Hepatocytes, which are the most pertinent model to reproduce the human liver functioning as they express 99% of the same genes.

Contents

In contrast to the historic hepatic line HepG2, HepaRG cells preserved various liver-specific functions, including the expression of CYP enzymes and transporters, the formation of bile canaliculi, and, the ability to be applied in 2D and 3D configuration.

History

In 1999, Dr. Christiane Guguen-Guillouzo and Dr. Christian Trépo collaborated on a medical and scientific project. During the course of their research, a tumor sample from a patient with cholangiocarcinoma and HCV was given to Sylvie Rumin to study hepatitis infection. Rumin observed a group of cells that resembled hepatic cells and gradually lost HCV infection markers. Philippe Gripon later developed these cells, finding that they had the ability to undergo complete hepatocyte differentiation while retaining all liver-specific functions. As a way to honor the contributions of Rumin and Gripon, the cells were named HepaRG, using the first letter of their last names. Since their discovery, many scientists characterized and used the HepaRG model in their studies. [1] [2] [3] [4]

Characterization

HepaRG cells are bipotent progenitors, capable of differentiating into both biliary and hepatocyte lineages. In culture, they are organized in well-delineated trabeculae with many bright canaliculi-like structures under 2D and 3D configurations. They are polarized cells that breathe aerobically, consume lactate, and contain as many mitochondria as the human hepatocytes. The cell line has the potential to express major properties of stem cells including high plasticity & transdifferentiation capacity.

The HepaRG cells have been found to express major nuclear receptors, [5] as well as drug and bile acids transporters, [6] and key hepatic nuclear factors. [7] [8] They also possess functional levels of phase I (CYP (CYP1A1/2, CYP2B6, CYP2Cs, CYP3A4, etc.) and II (UGT1A1, GSTA1, GSTA4, GSTM1) drug metabolizing enzymes. [9] Additionally, the HepaRG cells have functional mitochondria, hepatokine secretion abilities, and a suitable response to insulin. [10] [11]

One unique characteristic of HepaRG cells is that they can survive up to four weeks in culture, making them useful for long-term studies and repeated exposures to drugs and chemicals, unlike primary human hepatocytes. Moreover, the cells can be infected by HBV and HCV and support viral replication.

Undifferentiated hepatocyte-like cells appear in small, individualized, colonies HepaRGUndiff.jpg
Undifferentiated hepatocyte-like cells appear in small, individualized, colonies

The cells are available as undifferentiated growth-stage cells that can be grown in-house with the possibility of cell manipulation and amplification; or as fully differentiated cells that are ready and easy-to-use cells with high inter-assay reproducibility and proven functionality across multiple applications. They can also be used as spheroids and co-culture.

Use in research

HepaRG cells are considered fit-for-all-purpose cells as they were used in many applications ranging from drug development, drug metabolism and interaction assessment, chemical testing, assay validation, hepatotoxicity assessments, liver Biology, liver disease characterization, and virology studies.

Basic research

HepaRG cells are a versatile tool for modeling various viral and parasitic infections such as hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis E virus (HEV), and hepatitis delta virus (HDV). [12] [13]

They are also useful for studying the interconnected pathways involved in carbohydrate homeostasis and lipid metabolism. In contrast to many other cell lines, HepaRG cells are capable of regulating glycogenolysis and gluconeogenesis at levels similar to primary human hepatocytes, as well as retaining the response mechanisms associated with lipid-metabolizing enzymes. [14] [15]

Medical applications

HepaRG cells have shown potential in the field of regenerative medicine, specifically in the development of bio-artificial livers and liver-assisting devices due to their ability to be cultured in 3D bioreactors.

A study demonstrated that HepaRG cells can be incorporated into a microfluidic system to form a functional bio-artificial liver capable of detoxifying ammonia and other harmful substances. [16] In another study, a modular extracorporeal liver support system, which combines HepaRG cells with a bioartificial scaffold was created to support liver function. [17] This system was shown to be effective in removing toxins from the blood and supporting liver function in animal models.

Industrial applications

HepaRG is owned by the French National Institute of Health and Medical Research (INSERM) and since 2003, Biopredic International acquired the license of the cells and settled both the master and the working banks for preserving the stability of the line.

In vitro-ADME applications

HepaRG cells have many applications in in-vitro ADME (absorption, distribution, metabolism, and excretion) studies. They were used to study drug metabolism and toxicity, including phase I and phase II enzyme metabolism, induction, and inhibition. [18] [19] [20] Moreover, HepaRG cells have been used to study drug transporters, measure compound clearance, and predict metabolic stability as well as drug-drug interactions. Additionally, HepaRG has been used to evaluate acute and chronic drug toxicity, genotoxicity, and hepatotoxicity. [21] [22]

The high reproducibility of the drug-induced metabolic enzyme levels between batches enables routine high-throughput analysis of compound clearance. [23] [24]

Hepatotoxicity screening and mechanistic testing

HepaRG cells have been utilized for assessing drug-induced liver injury (DILI), including steatosis, cholestasis, and phospholipidosis, as well as for evaluating genotoxicity and carcinogenicity. [25] [26] [27] [28] Additionally, they have been employed for studying drug-induced mitochondrial toxicity, apoptosis, and inflammation. [29] HepaRG cells are advantageous for uptake and biliary secretion studies due to their expression of various uptake and efflux drug transporters, and the formation of tight junctions and bile canaliculi.

For instance, HepaRG cells have been used to evaluate the hepatotoxicity of compounds in drug development, such as acetaminophen, troglitazone, and valproic acid, as well as environmental toxins like aflatoxin B1 and ethanol. [30] [31] [32]

Related Research Articles

<span class="mw-page-title-main">Kavalactone</span> Group of chemical compounds

Kavalactones are a class of lactone compounds found in kava roots and Alpinia zerumbet. Some kavalactones are bioactive.

<span class="mw-page-title-main">Hepatotoxicity</span> Liver damage caused by a drug or chemical

Hepatotoxicity implies chemical-driven liver damage. Drug-induced liver injury (DILI) is a cause of acute and chronic liver disease caused specifically by medications and the most common reason for a drug to be withdrawn from the market after approval.

<span class="mw-page-title-main">Hepatocyte</span> Liver cell type

A hepatocyte is a cell of the main parenchymal tissue of the liver. Hepatocytes make up 80% of the liver's mass. These cells are involved in:

<span class="mw-page-title-main">Hep G2</span>

Hep G2 is a human liver cancer cell line.

<span class="mw-page-title-main">CYP3A4</span> Enzyme that metabolizes substances by oxidation

Cytochrome P450 3A4 is an important enzyme in the body, mainly found in the liver and in the intestine, which in humans is encoded by CYP3A4 gene. It oxidizes small foreign organic molecules (xenobiotics), such as toxins or drugs, so that they can be removed from the body. It is highly homologous to CYP3A5, another important CYP3A enzyme.

<span class="mw-page-title-main">CYP2E1</span> Protein-coding gene in the species Homo sapiens

Cytochrome P450 2E1 is a member of the cytochrome P450 mixed-function oxidase system, which is involved in the metabolism of xenobiotics in the body. This class of enzymes is divided up into a number of subcategories, including CYP1, CYP2, and CYP3, which as a group are largely responsible for the breakdown of foreign compounds in mammals.

Toxication, toxification or toxicity exaltation is the conversion of a chemical compound into a more toxic form in living organisms or in substrates such as soil or water. The conversion can be caused by enzymatic metabolism in the organisms, as well as by abiotic chemical reactions. While the parent drug are usually less active, both the parent drug and its metabolite can be chemically active and cause toxicity, leading to mutagenesis, teratogenesis, and carcinogenesis. Different classes of enzymes, such as P450 monooxygenases, epoxide hydrolase, or acetyltransferases can catalyze the process in the cell, mostly in the liver.

Glucuronidation is often involved in drug metabolism of substances such as drugs, pollutants, bilirubin, androgens, estrogens, mineralocorticoids, glucocorticoids, fatty acid derivatives, retinoids, and bile acids. These linkages involve glycosidic bonds.

<span class="mw-page-title-main">Bosentan</span> Medication

Bosentan, sold under the brand name Tracleer among others, is a dual endothelin receptor antagonist medication used in the treatment of pulmonary artery hypertension (PAH).

<span class="mw-page-title-main">CYP2C9</span> Enzyme protein

Cytochrome P450 family 2 subfamily C member 9 is an enzyme protein. The enzyme is involved in the metabolism, by oxidation, of both xenobiotics, including drugs, and endogenous compounds, including fatty acids. In humans, the protein is encoded by the CYP2C9 gene. The gene is highly polymorphic, which affects the efficiency of the metabolism by the enzyme.

<span class="mw-page-title-main">Constitutive androstane receptor</span> Protein-coding gene in humans

The constitutive androstane receptor (CAR) also known as nuclear receptor subfamily 1, group I, member 3 is a protein that in humans is encoded by the NR1I3 gene. CAR is a member of the nuclear receptor superfamily and along with pregnane X receptor (PXR) functions as a sensor of endobiotic and xenobiotic substances. In response, expression of proteins responsible for the metabolism and excretion of these substances is upregulated. Hence, CAR and PXR play a major role in the detoxification of foreign substances such as drugs.

<span class="mw-page-title-main">Aldehyde oxidase</span> Enzyme

Aldehyde oxidase (AO) is a metabolizing enzyme, located in the cytosolic compartment of tissues in many organisms. AO catalyzes the oxidation of aldehydes into carboxylic acid, and in addition, catalyzes the hydroxylation of some heterocycles. It can also catalyze the oxidation of both cytochrome P450 and monoamine oxidase (MAO) intermediate products. AO plays an important role in the metabolism of several drugs.

<span class="mw-page-title-main">CYP2B6</span> Protein-coding gene in the species Homo sapiens

Cytochrome P450 2B6 is an enzyme that in humans is encoded by the CYP2B6 gene. CYP2B6 is a member of the cytochrome P450 group of enzymes. Along with CYP2A6, it is involved with metabolizing nicotine, along with many other substances.

<span class="mw-page-title-main">Flunoxaprofen</span> Chemical compound

Flunoxaprofen, also known as Priaxim, is a chiral nonsteroidal anti-inflammatory drug (NSAID). It is closely related to naproxen, which is also an NSAID. Flunoxaprofen has been shown to significantly improve the symptoms of osteoarthritis and rheumatoid arthritis. The clinical use of flunoxaprofen has ceased due to concerns of potential hepatotoxicity.

Benoxaprofen, also known as Benoxaphen, is a chemical compound with the formula C16H12ClNO3. It is a non-steroidal anti-inflammatory drug (NSAID) of the propionic acid class, and was marketed under the brand name Opren in the United Kingdom and Europe by Eli Lilly and Company (commonly referred to as Lilly), and as Oraflex in the United States of America (USA). Lilly suspended sales of Oraflex in 1982 after reports from the British government and the United States Food and Drug Administration (US FDA) of adverse effects and deaths linked to the drug.

Cytochrome P450, family 3, subfamily A, also known as CYP3A, is a human gene locus. A homologous locus is found in mice.

cccDNA is a special DNA structure that arises during the propagation of some viruses in the cell nucleus and may remain permanently there. It is a double-stranded DNA that originates in a linear form that is ligated by means of DNA ligase to a covalently closed ring. In most cases, transcription of viral DNA can occur from the circular form only. The cccDNA of viruses is also known as episomal DNA or occasionally as a minichromosome.

<span class="mw-page-title-main">Menthofuran</span> Chemical compound

Menthofuran is an organic compound found in a variety of essential oils including that of pennyroyal. It is highly toxic and believed to be the primary toxin in pennyroyal responsible for its potentially fatal effects. After ingestion of menthofuran, it is metabolically activated to chemically reactive intermediates that are hepatotoxic.

Albert P. Li is president and CEO of In Vitro ADMET Laboratories (IVAL), Columbia, Maryland, and Malden, Massachusetts. For the past three decades, Li has devoted his scientific career to the advancement of scientific concepts and technologies to accurately predict human drug properties. His research is focused on the development and application of human-based in vitro experimental systems in drug discovery and development. He is a pioneer in the isolation, cryopreservation, and culturing of human hepatocytes and their application in the evaluation of drug metabolism, drug-drug interactions, and drug toxicity.

<span class="mw-page-title-main">Azamulin</span> Antibiotic

Azamulin is a pleuromutilin antibiotic. As of 2021, it is not marketed in the US or Europe.

References

  1. ↑ Anthérieu, Sébastien; Chesné, Christophe; Li, Ruoya; Camus, Sandrine; Lahoz, Agustin; Picazo, Laura; Turpeinen, Miia; Tolonen, Ari; Uusitalo, Jouko; Guguen-Guillouzo, Christiane; Guillouzo, André (March 2010). "Stable Expression, Activity, and Inducibility of Cytochromes P450 in Differentiated HepaRG Cells". Drug Metabolism and Disposition. 38 (3): 516–525. doi:10.1124/dmd.109.030197. PMID   20019244. S2CID   2134987.
  2. ↑ Gerets, H. H. J.; Tilmant, K.; Gerin, B.; Chanteux, H.; Depelchin, B. O.; Dhalluin, S.; Atienzar, F. A. (April 2012). "Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins". Cell Biology and Toxicology. 28 (2): 69–87. doi:10.1007/s10565-011-9208-4. PMC   3303072 . PMID   22258563.
  3. ↑ Jossé, Rozenn; Aninat, Caroline; Glaise, Denise; Dumont, Julie; Fessard, Valérie; Morel, Fabrice; Poul, Jean-Michel; Guguen-Guillouzo, Christiane; Guillouzo, André (June 2008). "Long-Term Functional Stability of Human HepaRG Hepatocytes and Use for Chronic Toxicity and Genotoxicity Studies". Drug Metabolism and Disposition. 36 (6): 1111–1118. doi:10.1124/dmd.107.019901. PMID   18347083. S2CID   29337628.
  4. ↑ Antoun, Joseph; Amet, Yolande; Simon, Brigitte; Dréano, Yvonne; Corlu, Anne; Corcos, Laurent; Salaun, Jean Pierre; Plée-Gautier, Emmanuelle (2006). "CYP4A11 is repressed by retinoic acid in human liver cells". FEBS Letters. 580 (14): 3361–3367. doi: 10.1016/j.febslet.2006.05.006 . PMID   16712844. S2CID   12620173.
  5. ↑ Bu, Hai-Zhi; Kang, Ping; Zhao, Ping; Pool, William F.; Wu, Ellen Y. (October 2005). "A Simple Sequential Incubation Method for Deconvoluting the Complicated Sequential Metabolism of Capravirine in Humans". Drug Metabolism and Disposition. 33 (10): 1438–1445. doi:10.1124/dmd.105.005413. PMID   16006566. S2CID   9884327.
  6. ↑ Bachour-El Azzi, Pamela; Sharanek, Ahmad; Abdel-Razzak, Ziad; Antherieu, Sebastien; Al-Attrache, Houssein; Savary, Camille C.; Lepage, Sylvie; Morel, Isabelle; Labbe, Gilles; Guguen-Guillouzo, Christiane; Guillouzo, André (September 2014). "Impact of Inflammation on Chlorpromazine-Induced Cytotoxicity and Cholestatic Features in HepaRG Cells". Drug Metabolism and Disposition. 42 (9): 1556–1566. doi:10.1124/dmd.114.058123. PMID   25002748. S2CID   1161113.
  7. ↑ Tascher, Georg; Burban, Audrey; Camus, Sandrine; Plumel, Marine; Chanon, Stéphanie; Le Guevel, Remy; Shevchenko, Valery; Van Dorsselaer, Alain; Lefai, Etienne; Guguen-Guillouzo, Christiane; Bertile, Fabrice (21 February 2019). "In-Depth Proteome Analysis Highlights HepaRG Cells as a Versatile Cell System Surrogate for Primary Human Hepatocytes". Cells. 8 (2): 192. doi: 10.3390/cells8020192 . PMC   6406872 . PMID   30795634.
  8. ↑ Yokoyama, Yuichi; Sasaki, Yoshifumi; Terasaki, Natsuko; Kawataki, Taku; Takekawa, Koji; Iwase, Yumiko; Shimizu, Toshinobu; Sanoh, Seigo; Ohta, Shigeru (1 May 2018). "Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures". Biological and Pharmaceutical Bulletin. 41 (5): 722–732. doi: 10.1248/bpb.b17-00913 . PMID   29445054.
  9. ↑ Li, Jinpeng; Settivari, Raja S.; LeBaron, Matthew J.; Marty, Mary Sue (1 December 2019). "Functional Comparison of HepaRG Cells and Primary Human Hepatocytes in Sandwich and Spheroid Culture as Repeated-Exposure Models for Hepatotoxicity". Applied in Vitro Toxicology. 5 (4): 187–195. doi:10.1089/aivt.2019.0008. S2CID   213691760.
  10. ↑ Iroz, Alison; Couty, Jean-Pierre; Postic, Catherine (August 2015). "Hepatokines: unlocking the multi-organ network in metabolic diseases". Diabetologia. 58 (8): 1699–1703. doi: 10.1007/s00125-015-3634-4 . ISSN   1432-0428. PMID   26032022. S2CID   7141228.
  11. ↑ Mallanna, Sunil K.; Duncan, Stephen A. (September 2013). "Differentiation of Hepatocytes from Pluripotent Stem Cells". Current Protocols in Stem Cell Biology. 26 (1): 1G.4.1–1G.4.13. doi:10.1002/9780470151808.sc01g04s26. PMC   3920294 . PMID   24510789.
  12. ↑ Lucifora, Julie; Xia, Yuchen; Reisinger, Florian; Zhang, Ke; Stadler, Daniela; Cheng, Xiaoming; Sprinzl, Martin F.; Koppensteiner, Herwig; Makowska, Zuzanna; Volz, Tassilo; Remouchamps, Caroline; Chou, Wen-Min; Thasler, Wolfgang E.; Hüser, Norbert; Durantel, David; Liang, T. Jake; Münk, Carsten; Heim, Markus H.; Browning, Jeffrey L.; Dejardin, Emmanuel; Dandri, Maura; Schindler, Michael; Heikenwalder, Mathias; Protzer, Ulrike (14 March 2014). "Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA". Science. 343 (6176): 1221–1228. Bibcode:2014Sci...343.1221L. doi:10.1126/science.1243462. PMC   6309542 . PMID   24557838.
  13. ↑ Tout, Issam; Gomes, Melissa; Ainouze, Michelle; Marotel, Marie; Pecoul, Timothee; Durantel, David; Vaccarella, Salvatore; Dubois, Bertrand; Loustaud-Ratti, Veronique; Walzer, Thierry; Alain, Sophie; Chemin, Isabelle; Hasan, Uzma (15 October 2018). "Hepatitis B Virus Blocks the CRE/CREB Complex and Prevents TLR9 Transcription and Function in Human B Cells". The Journal of Immunology. 201 (8): 2331–2344. doi: 10.4049/jimmunol.1701726 . ISSN   0022-1767. PMID   30185518. S2CID   52166654.
  14. ↑ Caron, Sandrine; Huaman Samanez, Carolina; Dehondt, Hélène; Ploton, Maheul; Briand, Olivier; Lien, Fleur; Dorchies, Emilie; Dumont, Julie; Postic, Catherine; Cariou, Bertrand; Lefebvre, Philippe; Staels, Bart (June 2013). "Farnesoid X Receptor Inhibits the Transcriptional Activity of Carbohydrate Response Element Binding Protein in Human Hepatocytes". Molecular and Cellular Biology. 33 (11): 2202–2211. doi:10.1128/MCB.01004-12. PMC   3648076 . PMID   23530060.
  15. ↑ Madec, Stéphanie; Cerec, Virginie; Plée-Gautier, Emmanuelle; Antoun, Joseph; Glaise, Denise; Salaun, Jean-Pierre; Guguen-Guillouzo, Christiane; Corlu, Anne (October 2011). "CYP4F3B expression is associated with differentiation of HepaRG human hepatocytes and unaffected by fatty acid overload". Drug Metabolism and Disposition: The Biological Fate of Chemicals. 39 (10): 1987–1996. doi:10.1124/dmd.110.036848. ISSN   1521-009X. PMID   21778351. S2CID   25447159.
  16. ↑ Schuessler, Teresa K.; Chan, Xin Yi; Chen, Huanhuan Joyce; Ji, Kyungmin; Park, Kyung Min; Roshan-Ghias, Alireza; Sethi, Pallavi; Thakur, Archana; Tian, Xi; Villasante, Aranzazu; Zervantonakis, Ioannis K.; Moore, Nicole M.; Nagahara, Larry A.; Kuhn, Nastaran Z. (1 October 2014). "Biomimetic Tissue–Engineered Systems for Advancing Cancer Research: NCI Strategic Workshop Report". Cancer Research. 74 (19): 5359–5363. doi:10.1158/0008-5472.CAN-14-1706. PMC   4184963 . PMID   25095784.
  17. ↑ Sauer, Igor M.; Gerlach, Joerg C. (August 2002). "Modular Extracorporeal Liver Support". Artificial Organs. 26 (8): 703–706. doi:10.1046/j.1525-1594.2002.06931_1.x. PMID   12139497.
  18. ↑ Gripon, Philippe; Rumin, Sylvie; Urban, Stephan; Le Seyec, Jacques; Glaise, Denise; Cannie, Isabelle; Guyomard, Claire; Lucas, Josette; Trepo, Christian; Guguen-Guillouzo, Christiane (26 November 2002). "Infection of a human hepatoma cell line by hepatitis B virus". Proceedings of the National Academy of Sciences. 99 (24): 15655–15660. Bibcode:2002PNAS...9915655G. doi: 10.1073/pnas.232137699 . PMC   137772 . PMID   12432097.
  19. ↑ Aninat, Caroline; Piton, Amélie; Glaise, Denise; Le Charpentier, Typhen; Langouët, Sophie; Morel, Fabrice; Guguen-Guillouzo, Christiane; Guillouzo, André (January 2006). "EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS". Drug Metabolism and Disposition. 34 (1): 75–83. doi:10.1124/dmd.105.006759. PMID   16204462. S2CID   16310821.
  20. ↑ Guillouzo, André; Corlu, Anne; Aninat, Caroline; Glaise, Denise; Morel, Fabrice; Guguen-Guillouzo, Christiane (May 2007). "The human hepatoma HepaRG cells: A highly differentiated model for studies of liver metabolism and toxicity of xenobiotics". Chemico-Biological Interactions. 168 (1): 66–73. doi:10.1016/j.cbi.2006.12.003. PMID   17241619.
  21. ↑ Le Vee, Marc; Jigorel, Emilie; Glaise, Denise; Gripon, Philippe; Guguen-Guillouzo, Christiane; Fardel, Olivier (May 2006). "Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line". European Journal of Pharmaceutical Sciences. 28 (1–2): 109–117. doi:10.1016/j.ejps.2006.01.004. PMID   16488578.
  22. ↑ Turpeinen, Miia; Tolonen, Ari; Chesne, Christophe; Guillouzo, André; Uusitalo, Jouko; Pelkonen, Olavi (June 2009). "Functional expression, inhibition and induction of CYP enzymes in HepaRG cells". Toxicology in Vitro. 23 (4): 748–753. doi:10.1016/j.tiv.2009.03.008. PMID   19328226.
  23. ↑ Gripon, Philippe; Rumin, Sylvie; Urban, Stephan; Le Seyec, Jacques; Glaise, Denise; Cannie, Isabelle; Guyomard, Claire; Lucas, Josette; Trepo, Christian; Guguen-Guillouzo, Christiane (26 November 2002). "Infection of a human hepatoma cell line by hepatitis B virus". Proceedings of the National Academy of Sciences. 99 (24): 15655–15660. Bibcode:2002PNAS...9915655G. doi: 10.1073/pnas.232137699 . PMC   137772 . PMID   12432097.
  24. ↑ Zanelli, Ugo; Caradonna, Nicola Pasquale; Hallifax, David; Turlizzi, Elisa; Houston, J. Brian (January 2012). "Comparison of Cryopreserved HepaRG Cells with Cryopreserved Human Hepatocytes for Prediction of Clearance for 26 Drugs". Drug Metabolism and Disposition. 40 (1): 104–110. doi:10.1124/dmd.111.042309. PMID   21998403. S2CID   49654.
  25. ↑ Bachour-El Azzi, Pamela; Sharanek, Ahmad; Abdel-Razzak, Ziad; Antherieu, Sebastien; Al-Attrache, Houssein; Savary, Camille C.; Lepage, Sylvie; Morel, Isabelle; Labbe, Gilles; Guguen-Guillouzo, Christiane; Guillouzo, André (September 2014). "Impact of Inflammation on Chlorpromazine-Induced Cytotoxicity and Cholestatic Features in HepaRG Cells". Drug Metabolism and Disposition. 42 (9): 1556–1566. doi:10.1124/dmd.114.058123. PMID   25002748. S2CID   1161113.
  26. ↑ Anthérieu, Sébastien; Rogue, Alexandra; Fromenty, Bernard; Guillouzo, André; Robin, Marie‐Anne (June 2011). "Induction of vesicular steatosis by amiodarone and tetracycline is associated with up‐regulation of lipogenic genes in heparg cells". Hepatology. 53 (6): 1895–1905. doi: 10.1002/hep.24290 . PMID   21391224. S2CID   8096472.
  27. ↑ Rogue, Alexandra; Anthérieu, Sébastien; Vluggens, Aurore; Umbdenstock, Thierry; Claude, Nancy; de la Moureyre-Spire, Catherine; Weaver, Richard J.; Guillouzo, André (April 2014). "PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells" (PDF). Toxicology and Applied Pharmacology. 276 (1): 73–81. doi:10.1016/j.taap.2014.02.001. PMID   24534255. S2CID   5229406.
  28. ↑ Anthérieu, Sébastien; Chesné, Christophe; Li, Ruoya; Guguen-Guillouzo, Christiane; Guillouzo, André (December 2012). "Optimization of the HepaRG cell model for drug metabolism and toxicity studies". Toxicology in Vitro. 26 (8): 1278–1285. doi:10.1016/j.tiv.2012.05.008. PMID   22643240.
  29. ↑ McGill, Mitchell R.; Yan, Hui-Min; Ramachandran, Anup; Murray, Gordon J.; Rollins, Douglas E.; Jaeschke, Hartmut (March 2011). "HepaRG cells: A human model to study mechanisms of acetaminophen hepatotoxicity". Hepatology. 53 (3): 974–982. doi:10.1002/hep.24132. PMC   3073317 . PMID   21319200.
  30. ↑ Sison-Young, Rowena L. C.; Mitsa, Dimitra; Jenkins, Rosalind E.; Mottram, David; Alexandre, Eliane; Richert, Lysiane; Aerts, Hélène; Weaver, Richard J.; Jones, Robert P.; Johann, Esther; Hewitt, Philip G.; Ingelman-Sundberg, Magnus; Goldring, Christopher E. P.; Kitteringham, Neil R.; Park, B. Kevin (October 2015). "Comparative Proteomic Characterization of 4 Human Liver-Derived Single Cell Culture Models Reveals Significant Variation in the Capacity for Drug Disposition, Bioactivation, and Detoxication". Toxicological Sciences. 147 (2): 412–424. doi:10.1093/toxsci/kfv136. PMC   4583060 . PMID   26160117.
  31. ↑ Tolosa, Laia; Gómez-Lechón, M. José; Jiménez, Nuria; Hervás, David; Jover, Ramiro; Donato, M. Teresa (July 2016). "Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis". Toxicology and Applied Pharmacology. 302: 1–9. doi:10.1016/j.taap.2016.04.007. PMID   27089845.
  32. ↑ Jossé, Rozenn; Aninat, Caroline; Glaise, Denise; Dumont, Julie; Fessard, Valérie; Morel, Fabrice; Poul, Jean-Michel; Guguen-Guillouzo, Christiane; Guillouzo, André (June 2008). "Long-Term Functional Stability of Human HepaRG Hepatocytes and Use for Chronic Toxicity and Genotoxicity Studies". Drug Metabolism and Disposition. 36 (6): 1111–1118. doi:10.1124/dmd.107.019901. PMID   18347083. S2CID   29337628.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.